08:32 AM EDT, 10/16/2025 (MT Newswires) -- Mira Pharmaceuticals ( MIRA ) said Thursday that new preclinical data showed that oral administration of marijuana analog Mira-55 provided "superior" pain normalization and significantly reduced inflammation, outperforming injected morphine in an established animal model of inflammatory pain.

These results support plans to move toward clinical development through an investigational new drug application with the US Food and Drug Administration for Mira-55 as a potential dual-acting non-opioid therapy for chronic inflammatory pain, Mira said.

The study marked the first time inflammation was directly measured along with pain, the company said. A prior study compared Mira-55 and morphine, both administered by injection.

Mira Pharmaceuticals ( MIRA ) shares were up more than 81% in recent premarket activity Thursday.